RCUSArcus Biosciences, Inc.
The Read
RCUS stock has shown moderate to high volatility before FDA decisions, with moves ranging from flat to about 18% on clinical or financial catalysts, but FDA-related events like the June 2026 ASCO and ESMO updates triggered declines of about 5–7% due to underwhelming trial results and lack of breakthrough data.
The schedule
- Thu15Oct
Evaluation of capital needs as cash reserves dwindle against high clinical trial expenditures.
- Wed23Dec
High‑impact clinical data update for domvanalimab (TIGIT) at AACR, with combination data in key solid tumors that can materially re-rate Arcus Biosciences, Inc. shares if efficacy and safety improve on prior curves.
- Sun10Jan
ASCO 2026 TIGIT and PD-1 combination data, evaluated from a $28.00 base, is a major binary catalyst that could either reinforce Arcus’s immuno-oncology thesis toward $33.00 or reset expectations back toward $33.00 if results remain only incremental.
- Sun10Jan
With shares heavily overbought (RSI 74.9) near $31.00, readthroughs from competitor TIGIT data are expected. A bullish surprise could extend momentum to $34.00, while disappointing readthroughs or exhaustion risk pulling the stock back to $26.50.
- Thu4Feb
Q3 results focusing on cost-containment measures and updated clinical timelines.
- Tue9Feb
Comprehensive FY26 review and establishing the 2027 corporate and clinical strategy.
- Tue9Feb
- Tue4May
Q1 2027 financial performance and potential shifts in partnership revenues.
Past
- Wed5Aug
Market assesses Q2 financials and cash burn against a stretched valuation nearing 52-week highs.
- Tue5May
Actual outcome: Bear · $24.78 at outcome
Arcus Biosciences reported a Q1 loss of $1.02 per share, which was wider than the consensus estimate of a $0.92 loss, despite beating revenue expectations. The wider-than-expected bottom-line loss overshadowed the revenue beat, prompting a negative reaction from investors. As a result, the stock fell 4.9% immediately following the release and continued to trend downward toward the $23 bear floor in the subsequent weeks.
Q1 2026 earnings and an updated cash runway view around $26.62 will test whether Arcus can sustain its recent premium after a strong FY25 print and mixed AACR TIGIT update.
- Wed25Feb
Actual outcome: Mixed · $20.37 at outcome
Arcus Biosciences met Q4 EPS estimates and reported strong FY25 results, supported by a robust $1.01B cash position to fund ongoing operations. The company also highlighted promising clinical data for its next-generation HIF-2α inhibitor, casdatifan, which demonstrated long-term effectiveness in treating advanced kidney cancer. While the stock's initial reaction was muted, this strong pipeline progress and solid financial footing ultimately drove shares toward the bull target in the months following the release.
Release of Q4 2025 financials. Investor focus will be on 2026 R&D expense guidance, operating cash burn rate, and the projected cash runway. Positive revenue recognition from Gilead collaboration or better-than-expected cash position supports the bull case.